drugset / Trial / NCT00126412

Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma

NCT00126412

Phase 3 Completed 251 enrolled GE Healthcare
NaSingle-groupOpen-labelDiagnostic

Summary

The study is designed to study the effectiveness of 123I-mIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroblastoma or phaeochromocytoma.

Timeline

Start
2005-08-02
Primary completion
2006-09-27
Completion
2006-09-27

Drugs

EvaluationDrugModalityDoseRoute
Subject 123I-mIBG Diagnostic / imaging agent 80 mbq Intravenous
Subject 123I-mIBG Diagnostic / imaging agent 370 mbq Intravenous